Free Trial

Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California logo
$1.76 +0.03 (+1.44%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIO

Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO).

Pacific Biosciences of California vs. Its Competitors

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

In the previous week, 10x Genomics had 16 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 21 mentions for 10x Genomics and 5 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.79 beat Pacific Biosciences of California's score of 0.35 indicating that 10x Genomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

10x Genomics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$610.78M2.50-$182.63M-$0.70-17.53
Pacific Biosciences of California$154.01M3.44-$309.85M-$2.29-0.77

10x Genomics presently has a consensus price target of $13.65, suggesting a potential upside of 11.27%. Pacific Biosciences of California has a consensus price target of $1.90, suggesting a potential upside of 7.65%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Pacific Biosciences of California.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
2 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.38
Pacific Biosciences of California
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

10x Genomics has a net margin of -13.13% compared to Pacific Biosciences of California's net margin of -336.40%. 10x Genomics' return on equity of -12.88% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-13.13% -12.88% -10.03%
Pacific Biosciences of California -336.40%-66.75%-16.90%

84.7% of 10x Genomics shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PACB vs. The Competition

MetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$530.15M$7.04B$6.14B$10.45B
Dividend YieldN/A1.18%5.73%4.78%
P/E Ratio-0.7726.8785.0627.10
Price / Sales3.4428.54570.65176.64
Price / CashN/A21.7037.3961.86
Price / Book0.955.1712.406.66
Net Income-$309.85M$178.09M$3.32B$276.79M
7 Day Performance15.36%-3.08%-0.23%-1.40%
1 Month Performance43.50%4.61%9.56%5.64%
1 Year Performance-14.32%3.23%71.76%37.04%

Pacific Biosciences of California Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACB
Pacific Biosciences of California
1.0312 of 5 stars
$1.77
+1.4%
$1.90
+7.6%
-17.1%$530.15M$154.01M-0.77730
TXG
10x Genomics
3.8189 of 5 stars
$11.60
+1.1%
$13.65
+17.7%
-25.3%$1.44B$610.78M-16.571,240Trending News
Analyst Forecast
Analyst Revision
HBIO
Harvard Bioscience
4.3003 of 5 stars
$0.42
+0.5%
$2.00
+374.3%
-82.7%$18.78M$94.14M-0.32490
TMO
Thermo Fisher Scientific
4.8791 of 5 stars
$524.80
flat
$593.43
+13.1%
-12.2%$198.17B$42.88B30.35125,000Trending News
Upcoming Earnings
Analyst Forecast
Analyst Revision
Gap Up
A
Agilent Technologies
4.5529 of 5 stars
$138.43
+1.3%
$148.69
+7.4%
-3.8%$39.24B$6.79B32.4917,900Analyst Forecast
Analyst Revision
MTD
Mettler-Toledo International
3.9098 of 5 stars
$1,289.13
+1.2%
$1,336.50
+3.7%
-10.3%$26.56B$3.87B32.6417,300Positive News
WAT
Waters
4.4059 of 5 stars
$336.83
+1.8%
$377.56
+12.1%
-7.5%$20.05B$2.96B30.377,600
ILMN
Illumina
4.7886 of 5 stars
$95.03
+1.2%
$123.56
+30.0%
-37.0%$14.61B$4.28B12.039,030Trending News
Analyst Revision
TECH
Bio-Techne
4.6952 of 5 stars
$59.65
+1.7%
$70.17
+17.6%
-19.0%$9.29B$1.22B129.683,100Trending News
Analyst Forecast
Analyst Revision
CRL
Charles River Laboratories International
4.1065 of 5 stars
$170.85
+2.3%
$179.93
+5.3%
-11.8%$8.41B$4.03B-128.4620,100News Coverage
Analyst Upgrade
Analyst Revision
BIO
Bio-Rad Laboratories
4.0884 of 5 stars
$303.56
+2.0%
$333.50
+9.9%
-10.7%$8.21B$2.57B25.887,700News Coverage
Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:PACB) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners